SEC Comment Letter 0000000000-24-003283 to Adverum Biotechnologies, Inc. (ADVM) (CIK 0001501756)
Adverum Biotechnologies, Inc. (ADVM) (CIK 0001501756)
Date: March 26, 2024 · CIK: 0001501756 · Accession: 0000000000-24-003283
AI Filing Summary & Sentiment
File numbers found in text: 333-278157
Letter
United States securities and exchange commission logo March 26, 2024 Laurent Fischer President and Chief Executive Officer Adverum Biotechnologies, Inc. 100 Cardinal Way Redwood City, CA 94063 Re:Adverum Biotechnologies, Inc. Registration Statement on Form S-3 Filed March 21, 2024 File No. 333-278157 Dear Laurent Fischer: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jason Drory at 202-551-8342 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Julia R. Boesch
Show Raw Text
United States securities and exchange commission logo
March 26, 2024
Laurent Fischer
President and Chief Executive Officer
Adverum Biotechnologies, Inc.
100 Cardinal Way
Redwood City, CA 94063
Re:Adverum Biotechnologies, Inc.
Registration Statement on Form S-3
Filed March 21, 2024
File No. 333-278157
Dear Laurent Fischer:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Jason Drory at 202-551-8342 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Julia R. Boesch